Arrowpoint Investment Partners’s Merck MRK Stock Holding History

Arrowpoint Investment Partners’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-24,500	Closed	-$2.06M	–	133
2025 Q3	$2.06M	Buy	+24,500	New	+$2.02M	2.05%	11
2025 Q2	–	Sell	-1,400	Closed	-$126K	–	564
2025 Q1	$126K	Buy	+1,400	New	+$131K	0.01%	810

Other funds holding MRK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowpoint Investment Partners's MRK Position: Q1 2026 in Review

Arrowpoint Investment Partners sold out of Merck (MRK) in Q1 2026, closing a stake of 46,686 shares — an estimated $4.91M sold.

Arrowpoint Investment Partners first reported a position in MRK in Q1 2025 and held it in 2 quarters. The position peaked at $4.91M in Q4 2025. 3,781 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

Arrowpoint Investment Partners reported no remaining Merck position as of Q1 2026 after selling out during the quarter.
Arrowpoint Investment Partners sold 46,686 Merck shares in Q1 2026, an estimated $4.91M.
Arrowpoint Investment Partners first reported a position in Merck in Q1 2025 and held it in 2 quarters.
Arrowpoint Investment Partners's Merck position peaked at $4.91M in Q4 2025.
3,781 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.